ImmunoPrecise Antibodies Ltd. (IPA)
After hours:
| Previous close | 1.2200 |
| Open | 1.2300 |
| Bid | 1.3000 x 100 |
| Ask | 1.3600 x 100 |
| Day's range | 1.2092 - 1.3300 |
| 52-week range | 0.9400 - 4.2200 |
| Volume | |
| Avg. volume | 597,936 |
| Market cap | 34.736M |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings date | 05 July 2024 - 09 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.99 |
Business WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
VICTORIA, British Columbia, March 28, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. This collaboration int
Business WireIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
VICTORIA, British Columbia, March 20, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby s
Business WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
VICTORIA, British Columbia, March 14, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its third quarter of the 2024 fiscal year ("FY24"), which ended January 31, 2024.
